axicabtagene ciloleucel CAR-T
Selected indexed studies
- Current Progress in CAR-T Cell Therapy for Solid Tumors. (Int J Biol Sci, 2019) [PMID:31754328]
- CAR T-cell therapy for B-cell lymphoma. (Curr Probl Cancer, 2022) [PMID:35012754]
- A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. (Nat Med, 2024) [PMID:38977912]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Current Progress in CAR-T Cell Therapy for Solid Tumors. (2019) pubmed
- CAR T-cell therapy for B-cell lymphoma. (2022) pubmed
- A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. (2024) pubmed
- Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL. (2018) pubmed
- Tuning the Antigen Density Requirement for CAR T-cell Activity. (2020) pubmed
- Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing. (2025) pubmed
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. (2019) pubmed
- Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. (2022) pubmed
- Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. (2020) pubmed
- Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. (2023) pubmed